<DOC>
	<DOCNO>NCT01304173</DOCNO>
	<brief_summary>This observational study involve retrospective review medical record adult patient treat intravesical valrubicin bladder carcinoma situ ( CIS ) since October 2009 .</brief_summary>
	<brief_title>Retrospective Chart Review Valstar</brief_title>
	<detailed_description>Initial treatment bladder CIS TURBT follow intravesical immunotherapy BCG . Valrubicin approve FDA treatment BCG-refractory bladder CIS patient immediate cystectomy would associate unacceptable morbidity mortality . The recommended course therapy 6 dos 800 mg administer intravesically week . While benefit risk profile valrubicin establish several clinical trial , current data effectiveness tolerability use clinical practice lack . This protocol outline retrospective study evaluate effectiveness , safety tolerability intravesical valrubicin treatment NMIBC clinical practice setting .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>age 18 year old great diagnosis CIS ( physician define medical record ) treat least one IVe dose valrubicin since 10/2009 complete prescribed therapy longer receive therapy time study enrollment willing able provide inform consent ( unless waiver inform consent applicable place clinical site per Chapter 45 CFR part 46 Subpart A 46.117 route administration valrubicin intravesical</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>BCG</keyword>
	<keyword>refractory</keyword>
	<keyword>NMIBC</keyword>
	<keyword>CIS</keyword>
	<keyword>non-muscle invasive</keyword>
</DOC>